MA33974B1 - Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek - Google Patents

Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Info

Publication number
MA33974B1
MA33974B1 MA34821A MA34821A MA33974B1 MA 33974 B1 MA33974 B1 MA 33974B1 MA 34821 A MA34821 A MA 34821A MA 34821 A MA34821 A MA 34821A MA 33974 B1 MA33974 B1 MA 33974B1
Authority
MA
Morocco
Prior art keywords
inhibitor
combinations
pi3k
mek
kinase inhibitor
Prior art date
Application number
MA34821A
Other languages
Arabic (ar)
English (en)
Inventor
Marcia Belvin
Iris T Chan
Lori Friedman
Klause P Hoeflich
John Prescott
Jeffrey Wallin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33974(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33974B1 publication Critical patent/MA33974B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des procédés de traitement d'un patient présentant des tumeurs solides localement avancées ou métastasiques par une combinaison d'un inhibiteur de phosphatidylinositol 3-kinase (pi 3-kinase ou pi3k) et un inhibiteur de kinase de kinase de protéine activée par le mitogène.
MA34821A 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek MA33974B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (fr) 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Publications (1)

Publication Number Publication Date
MA33974B1 true MA33974B1 (fr) 2013-02-01

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34821A MA33974B1 (fr) 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Country Status (24)

Country Link
US (1) US20110086837A1 (fr)
EP (1) EP2488178B1 (fr)
JP (2) JP2013507415A (fr)
KR (1) KR101489045B1 (fr)
CN (1) CN102740851B (fr)
AR (1) AR078588A1 (fr)
AU (1) AU2010314287A1 (fr)
BR (1) BR112012008483A2 (fr)
CA (1) CA2776944A1 (fr)
CL (1) CL2012000913A1 (fr)
CO (1) CO6531463A2 (fr)
CR (1) CR20120173A (fr)
EC (1) ECSP12011865A (fr)
ES (1) ES2609767T3 (fr)
IL (1) IL219105A0 (fr)
MA (1) MA33974B1 (fr)
MX (1) MX345155B (fr)
NZ (1) NZ599939A (fr)
PE (1) PE20121816A1 (fr)
PH (1) PH12012500709A1 (fr)
RU (1) RU2563193C2 (fr)
TW (1) TWI428336B (fr)
WO (1) WO2011054620A1 (fr)
ZA (1) ZA201202618B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527703A (ja) 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
DK2385832T3 (en) 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
ME02451B (fr) 2011-04-01 2016-09-20 Curis Inc Inhibiteur de phosphoïnositide 3-kinase avec fraction de liaison au zinc
MY193562A (en) * 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013066483A1 (fr) * 2011-08-31 2013-05-10 Novartis Ag Combinaisons synergiques d'inhibiteurs de pi3k et de mek
CA2849331A1 (fr) 2011-10-13 2013-04-18 Genentech, Inc. Traitement de l'hypochlorhydrie induite pharmacologiquement
JP6251682B2 (ja) * 2011-10-28 2017-12-20 ジェネンテック， インコーポレイテッド メラノーマ治療の治療の組み合わせ及び方法
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
CA2869152A1 (fr) * 2012-04-06 2013-10-10 Sanofi Methodes de traitement du cancer a l'aide d'un inhibiteur de pi3k et d'un inhibiteur de mek
WO2013157648A1 (fr) * 2012-04-19 2013-10-24 国立大学法人九州大学 Composition pharmaceutique
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
JP2015529656A (ja) 2012-08-02 2015-10-08 ジェネンテック， インコーポレイテッド 抗ｅｔｂｒ抗体および免疫複合体
CN104717979A (zh) 2012-08-02 2015-06-17 基因泰克公司 抗etbr抗体和免疫偶联物
PT2884979T (pt) * 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2945387T3 (es) * 2014-02-07 2023-06-30 Verastem Inc Procedimientos y composiciones para tratar el crecimiento celular anormal
CA2954508A1 (fr) 2014-07-15 2016-01-21 Genentech, Inc. Compositions de traitement du cancer a l'aide d'antagonistes de liaison a l'axe pd-1 et d'inhibiteurs de mek
WO2016040806A1 (fr) * 2014-09-11 2016-03-17 The Regents Of The University Of California Inhibiteurs de mtorc1
WO2020055840A1 (fr) 2018-09-11 2020-03-19 Curis Inc. Polythérapie avec un inhibiteur de phosphoinositide 3-kinase ayant une fraction de liaison au zinc
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (fr) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (fr) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
WO1995026956A1 (fr) * 1994-04-01 1995-10-12 Shionogi & Co., Ltd. Derive d'oxime et bactericide le contenant en tant qu'ingredient actif
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US6960614B2 (en) * 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004218463B2 (en) * 2003-03-03 2009-07-16 Array Biopharma, Inc. p38 inhibitors and methods of use thereof
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (fr) * 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CA3052368A1 (fr) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines comme inhibiteurs de mek
PT2024372E (pt) * 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
JP2010500994A (ja) * 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
EP2114949A1 (fr) * 2006-12-07 2009-11-11 F.Hoffmann-La Roche Ag Composés inhibant la phosphoinositide 3 kinase et procédés d'utilisation
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
CA2831932A1 (fr) * 2011-04-01 2012-10-04 Genentech, Inc. Combinaisons de composes inhibiteurs d'akt et mek, et procedes d'utilisation

Also Published As

Publication number Publication date
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
KR101489045B1 (ko) 2015-02-02
PE20121816A1 (es) 2013-01-02
NZ599939A (en) 2014-02-28
CN102740851A (zh) 2012-10-17
ZA201202618B (en) 2014-10-29
AR078588A1 (es) 2011-11-16
TWI428336B (zh) 2014-03-01
CL2012000913A1 (es) 2012-09-14
CO6531463A2 (es) 2012-09-28
WO2011054620A1 (fr) 2011-05-12
HK1175125A1 (en) 2013-06-28
IL219105A0 (en) 2012-06-28
US20110086837A1 (en) 2011-04-14
JP5745678B2 (ja) 2015-07-08
MX345155B (es) 2017-01-18
JP2013507415A (ja) 2013-03-04
BR112012008483A2 (pt) 2019-09-24
CA2776944A1 (fr) 2011-05-12
AU2010314287A2 (en) 2012-07-12
CN102740851B (zh) 2013-12-18
PH12012500709A1 (en) 2012-10-29
EP2488178B1 (fr) 2016-11-16
KR20120064132A (ko) 2012-06-18
JP2015038110A (ja) 2015-02-26
TW201118082A (en) 2011-06-01
AU2010314287A1 (en) 2012-05-03
RU2012118974A (ru) 2013-11-20
EP2488178A1 (fr) 2012-08-22
ES2609767T3 (es) 2017-04-24
ECSP12011865A (es) 2012-06-29
CR20120173A (es) 2012-07-04

Similar Documents

Publication Publication Date Title
MA33974B1 (fr) Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
BR112012008818A2 (pt) anticorpos monoclonais para progastrina e seus usos.
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
DE502007002289D1 (de) Methacrylatharze zur herstellung von fahrbahnmarkierungen
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
NZ588033A (en) Methods of treating a mif-mediated disorder
MX2010003013A (es) Inhibicion de angiogenesis.
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
CR20120653A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
BR112014004577A2 (pt) inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
EA201200087A1 (ru) 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k